Monthly Archives: November 2013

Nolvadex Tamoxifen as a Selective Estrogen Receptor Modulator

Estrogen is a hormone present in the females that is responsible for normal menstrual cycle and for the development of secondary sexual characteristics. These secondary sexual characteristics include development of breasts, the reproductive system and a number of other changes that take place in a female body during puberty.

An excess of this hormone can cause a number of complications in the females that include development of breast cancers and deep vein thrombosis i.e. development of clots in veins, especially deep veins of legs. Excessive estrogen is also responsible for excessive weight gain, menstrual disturbances, ovarian cysts, migraine headaches, endometriosis, and fibroids.

Nolvadex Tamoxifen is an estrogen blocker in some tissues and an estrogen enhancer in others. It blocks the harmful effects of estrogen and at the same time retains its beneficial effects. It is basically a competitive partial agonist inhibitor of estrogen receptors in our body and the first drug of its kind. Nolvadex Tamoxifen competes with estrogen for binding sites and can suppress or enhance the effects depending on the tissue. Due to this reason it is classified into a special group known as selective estrogen receptor modulator or SERMs in short. Continue reading